In recent years we've seen European biopharma groups engineer some major breakthroughs in drug and vaccine development. From mRNA to the latest in cell and gene therapies and much more, the continent's top talent has grabbed the attention of the global industry, illustrating the new mainstream path ahead as record levels of capital flow into the field. What's ahead for Europe — and worldwide partnerships in the US and Asia — as the world continues to move into a post-pandemic world? We'll talk to a group of leading figures.